Angiotensin II downregulates ACE2-mediated enhancement of MMP-2 activity in human cardiofibroblasts.

Angiotensin converting enzyme II (ACE2) is a component of the renin-angiotensin system (RAS) that negatively regulates angiotensin II (Ang II). Ang II, in turn, affects the expression of matrix metalloproteinases (MMPs) to induce heart remodeling. The specific mechanisms by which ACE2 regulates MMP-2, however, remain unclear. The aim of this study was to investigate the regulatory relationships between Ang II, ACE2, and MMP-2. ACE2 expression was upregulated and downregulated in human cardiofibroblasts (HCFs) by lentiviral infection. Effects on MMP-2 activity, shed ACE2 activity, extracellular signal-regulated kinase (ERK) signaling pathway, and ADAM metallopeptidase domain 17 (ADAM17) expression were assessed. ACE2 increased MMP-2 activity, and Ang II inhibited this effect through the Ang II type-1 receptor (AT1R) and ERK1/2 signaling pathway. Ang II also reduced the effect of ACE2 on ERK1/2 levels, the activity of shed ACE2, and adam17 expression in HCFs. Additionally, these Ang II-mediated reductions could be attenuated by AT1R antagonist valsartan. In conclusion, these data help to clarify how ACE2 and Ang II interact to regulate MMP-2 and control tissue remodeling in heart disease.

Circulating matrix metalloproteinase-2 and -9 enzyme activities in the children with ventricular septal defect.

Ventricular septal defect (VSD) is the most common form of congenital heart diseases. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases involved in causal cardiac tissue remodeling. We studied the changes of circulating MMP-2 and MMP-9 activities in the patients with VSD severity and closure. There were 96 children with perimembranous VSD enrolled in this study. We assigned the patients into three groups according to the ratio of VSD diameter/diameter of aortic root (Ao). They were classified as below: Trivial (VSD/Ao ratio ≤ 0.2), Small (0.2 < VSD/Ao ≤ 0.3) and Median (0.3 < VSD/Ao) group. Plasma MMP-2 and MMP-9 activities were assayed by gelatin zymography. There was a significant higher MMP-2 activity in the VSD (Trivial, Small and Median) groups compared with that in Control group. The plasma MMP-9 activity showed a similar trend as the findings in MMP-2 activity. After one year follow-up, a significant difference in the MMP-9 activity was found between VSD spontaneous closure and non-closure groups. In conclusion, a positive trend between the severity of VSD and activities of MMP-2 and MMP-9 was found. Our data imply that MMP-2 and MMP-9 activities may play a role in the pathogenesis of VSD.

Estimation and prediction of drug therapy on the termination of atrial fibrillation by autoregressive model with exogenous inputs.

Atrial fibrillation (AF) is the most frequent cardiac arrhythmia seen in clinical practice. Several therapeutical approaches have been developed to terminate the AF and the effects are evaluated by the reduction of the wavelet number after the treatments. Most of the previous studies focus on modeling and analysis the mechanism, and the characteristic of AF. But no one discusses about the prediction of the result after the drug treatment. This paper is the first study to predict whether the drug treatment for AF is active or not. In this paper, the linear autoregressive model with exogenous inputs (ARX) that models the system output-input relationship by solving linear regression equations with least squares method was developed and applied to estimate the effects of pharmacological therapy on AF. Recordings (224-site bipolar recordings) of plaque electrode arrays placed on the right and left atria of pigs with sustained AF induced by rapid atrial-pacing were used to train and test the ARX models. The cardiac mapping data from twelve pigs treated with intravenous administration of antiarrhythmia drug, propafenone (PPF) or dl-sotalol (STL), was evaluated. The recordings of cardiac activity before the drug treatment were input to the model and the model output reported the estimated wavelet number of atria after the drug treatment. The results show that the predicting accuracy rate corresponding to the PPF and STL treatment was 100% and 92%, respectively. It is expected that the developed ARX model can be further extended to assist the clinical staffs to choose the effective treatments for the AF patients in the future.

Identifying the regulative role of NF-κB binding sites within promoter region of human matrix metalloproteinase 9 (mmp-9) by TNF-α induction.

Matrix metalloproteinase 9 (MMP-9), a member of MMP family, is involved in many physiological processes, including cardiovascular disease (CVD). Tumor necrosis factor-α (TNF-α) is considered a cytokine with pleiotropic biological capabilities and leads to the process of CVD when TNF-α is abnormally released and stimulates MMP-9 expression and activation. In this study, we investigated the molecular mechanism of TNF-α-regulated MMP-9 expression. The experimental results confirm that TNF-α could upregulate MMP-9 expression in heart myoblast H9c2 cells of rat. To evaluate the MMP-9 regulation at transcriptional level, a DNA fragment of 2.2 kb (-2168/+18) of human mmp-9 promoter region was cloned and constructed in a vector of luciferase reporter gene. The 2.2-kb sequences were identified as having three candidate nuclear factor-κ B (NF-κB) binding sites: NF-κB I (-1418/-1409), NF-κB II (-626/-617), and NF-κB III (-353/-345). A series of reporter vectors with the mutated NF-κB sites of mmp-9 promoter sequences were constructed and transfected into H9c2 cells. The results show that the NF-κB II binding site (-626/-617) within the promoter region of mmp-9 plays a key role in upregulation of mmp-9 expression by TNF-α induction. In addition, we also first identified that the NF-κB I, similar to c-Rel, might be one of the NF-κB families to regulate mmp-9 expression.

ACE/ACE2 ratio and MMP-9 activity as potential biomarkers in tuberculous pleural effusions.

OBJECTIVE: Pleural effusion is common problem, but the rapid and reliable diagnosis for specific pathogenic effusions are lacking. This study aimed to identify the diagnosis based on clinical variables to differentiate pleural tuberculous exudates from other pleural effusions. We also investigated the role of renin-angiotensin system (RAS) and matrix metalloproteinase (MMPs) in the pathogenesis of pleural exudates. EXPERIMENTAL DESIGN: The major components in RAS and extracellular matrix metabolism, including angiotensin converting enzyme (ACE), ACE2, MMP-2 and MMP-9 activities, were measured and compared in the patients with transudative (n = 45) and exudative (n = 80) effusions. The exudative effusions were come from the patients with tuberculosis (n = 20), pneumonia (n = 32), and adenocarcinoma (n = 28). RESULTS: Increased ACE and equivalent ACE2 activities, resulting in a significantly increased ACE/ACE2 ratio in exudates, were detected compared to these values in transudates. MMP-9 activity in exudates was significantly higher than that in transudates. The significant correlation between ACE and ACE2 activity that was found in transudates was not found in exudates. Advanced analyses showed significantly increased ACE and MMP-9 activities, and decreased ACE2 activity in tuberculous pleural effusions compared with those in pneumonia and adenocarcinoma effusions. The results indicate that increased ACE and MMP-9 activities found in the exudates were mainly contributed from a higher level of both enzyme activities in the tuberculous pleural effusions. CONCLUSION: Interplay between ACE and ACE2, essential functions in the RAS, and abnormal regulation of MMP-9 probably play a pivotal role in the development of exudative effusions. Moreover, the ACE/ACE2 ratio combined with MMP-9 activity in pleural fluid may be potential biomarkers for diagnosing tuberculous pleurisy.

Effects of diosgenin on myometrial matrix metalloproteinase-2 and -9 activity and expression in ovariectomized rats.

Diosgenin, a traditional Yam extraction, has been used in hormone replacement for menopausal women. We aimed to investigate the influences of diosgenin administration upon the MMP-2 and -9 activity and expression and reproductive hormones of ovariectomized (OVX) rats, a model of menopausal status. Seven-week old female Wistar rats with bilateral OVX or sham operation (controls) were divided and administered different dosages of diosgenin (0, 10, 50, or 100 mg/kg/day) for 8 weeks. Serum was then sampled for progesterone (P4) and estradiol (E2) assay and uterine horns harvested. Myometrial MMP-2 and -9 activity and expression were surveyed and myometrial collagen expression was also assayed. The results show higher body weight in OVX rats across the 8 weeks post surgery and no significant differences were noted among OVX or Sham rats with diosgenin supplements. There were lower P4 and E2 concentrations in OVX rats compared to Sham rats, and higher P4 concentration of Sham rats post diosgenin supplement. MMP-2 and -9 mRNA expression and activity was lower in OVX rats, although higher MMP-2 and lower MMP-9 activity/mRNA expression was observed in OVX rats post diosgenin supplementation. Collagen mRNA expression was higher in OVX rats compared to Sham controls, and diosgenin administration decreased collagen mRNA expression in OVX rats. In conclusion, diosgenin is associated with gelatinase expression and collagen metabolism in OVX rats. Diosgenin administration can partially reverse the effects of OVX upon MMP functions and hormone status. Adequate diosgenin supplement might modulate myometrial gelatinase expression and collagen metabolism in menopausal subjects.

Identifying the regulatory element for human angiotensin-converting enzyme 2 (ACE2) expression in human cardiofibroblasts.

Angiotensin-converting enzyme 2 (ACE2) has been proposed as a potential target for cardioprotection in regulating cardiovascular functions, owing to its key role in the formation of the vasoprotective peptides angiotensin-(1-7) from angiotensin II (Ang II). The regulatory mechanism of ace2 expression, however, remains to be explored. In this study, we investigated the regulatory element within the upstream of ace2. The human ace2 promoter region, from position -2069 to +20, was cloned and a series of upstream deletion mutants were constructed and cloned into a luciferase reporter vector. The reporter luciferase activity was analyzed by transient transfection of the constructs into human cardiofibroblasts (HCFs) and an activating domain was identified in the -516/-481 region. Deletion or reversal of this domain within ace2 resulted in a significant decrease in promoter activity. The nuclear proteins isolated from the HCFs formed a DNA-protein complex with double stranded oligonucleotides of the -516/-481 domain, as detected by electrophoretic mobility shift assay. Site-directed mutagenesis of this region identified a putative protein binding domain and a potential binding site, ATTTGGA, homologous to that of an Ikaros binding domain. This regulatory element was responsible for Ang II stimulation via the Ang II-Ang II type-1 receptor (AT1R) signaling pathway, but was not responsible for pro-inflammatory cytokines TGF-ß1 and TNF-α. Our results suggest that the nucleotide sequences -516/-481 of human ace2 may be a binding domain for an as yet unidentified regulatory factor(s) that regulates ace2 expression and is associated with Ang II stimulation.

Regulation of angiotensin converting enzyme II by angiotensin peptides in human cardiofibroblasts.

Numerous studies have suggested that angiotensin peptides modulate the expression of angiotensin converting enzyme II (ACE2) in the cardiovascular system, but the molecular mechanisms remain poorly understood. In the present study, human cardiac fibroblasts (HCF) were used to test the regulatory effects of angiotensin II (Ang II) and angiotensin-(1-7) [Ang-(1-7)] on ACE2 expression. The results show that Ang II upregulates ACE2 expression. This action is modulated through activation of Ang II type 1 receptor (AT1R). Ang II-mediated ACE2 upregulation was blocked by antagonists of AT1R and ERK-MAPK signaling pathways. Additionally, Ang-(1-7) increased ACE2 expression, and this upregulation was inhibited by Ang-(1-7) Mas receptor blockade. Our results further reveal that the activation of p-ERK1/2 proteins plays a critical role in upregulating ACE2 in Ang-(1-7)-stimulated HCF cells. This effect occurs independently of the Ang II-AT1R signaling pathway. In conclusion, we propose that Ang II-upregulated ACE2 may increase Ang-(1-7) formation from Ang II, and that ACE2 expression is further enhanced by Ang-(1-7) in a positive feedback loop.

Reduction of CO2 by a high-density culture of Chlorella sp. in a semicontinuous photobioreactor.

The microalga incorporated photobioreactor is a highly efficient biological system for converting CO2 into biomass. Using microalgal photobioreactor as CO2 mitigation system is a practical approach for elimination of waste gas from the CO2 emission. In this study, the marine microalga Chlorella sp. was cultured in a photobioreactor to assess biomass, lipid productivity and CO2 reduction. We also determined the effects of cell density and CO2 concentration on the growth of Chlorella sp. During an 8-day interval cultures in the semicontinuous cultivation, the specific growth rate and biomass of Chlorella sp. cultures in the conditions aerated 2-15% CO2 were 0.58-0.66 d(-1) and 0.76-0.87 gL(-1), respectively. At CO2 concentrations of 2%, 5%, 10% and 15%, the rate of CO2 reduction was 0.261, 0.316, 0.466 and 0.573 gh(-1), and efficiency of CO2 removal was 58%, 27%, 20% and 16%, respectively. The efficiency of CO2 removal was similar in the single photobioreactor and in the six-parallel photobioreactor. However, CO2 reduction, production of biomass, and production of lipid were six times greater in the six-parallel photobioreactor than those in the single photobioreactor. In conclusion, inhibition of microalgal growth cultured in the system with high CO2 (10-15%) aeration could be overcome via a high-density culture of microalgal inoculum that was adapted to 2% CO2. Moreover, biological reduction of CO2 in the established system could be parallely increased using the photobioreactor consisting of multiple units.

Guided tissue regeneration for using a chitosan membrane: an experimental study in rats.

Barrier membranes are employed clinically to deflect the growth of gingival tissues away from root surface. They provide an isolated space over the regions with the defective tissues that allow the relatively slow growing periodontal ligament fibroblasts to be repopulated onto the root surface. Several makes of bioabsorbable membranes are now commercially available. In this study, we have employed chitosan as barrier membrane material and evaluated it for a guided tissue regeneration application. Three types of chitosan membranes: Chi-NaOH, Chi-Na(5)P(3)O(10), and Chi-Na(2)SO(3)(each was gelated by NaOH, crosslinked by Na(5)P(3)O(10) and Na(2)SO(3), respectively), were prepared to be evaluated by the following categories: the mechanical strength to create an effective space, the rapid rate to reach hydrolytic equilibrium in phosphate-buffered solution, and the ease of clinical manipulative operations. Consequently, standardized, transosseous and critical sized skull defects were made in adult rats and the defective regions were covered with the specifically prepared chitosan membranes. After 4 weeks of recovering, varying degrees of bone healing were observed beneath the chitosan membranes in comparison to the control group. The chitosan covered regions showed a clear boundary space between connective tissues and bony tissues. Apparently, this process resulted in a good cell occlusion and beneficial osteogenesis effect to the bone. As for the control group, the bone defect was filled with connective tissue, and a destruction of the integrity of newly formed bone was observed. Among the chitosan membranes tested in this study, Chi-NaOH membrane provided a higher percentage of new bone formation than those from the Chi-Na(5)P(3)O(10) and Chi-Na(2)SO(3) families.